IBRX FY 2020 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$605,000+1307.0% YoY

Gross Profit

$605,000100.0% margin

Operating Income

-$221M-36509.1% margin

Net Income

-$222M-36669.6% margin

EPS (Diluted)

$-0.59

Cash Flow

Operating Cash Flow

-$172M

Free Cash Flow

-$173M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$221M

Total Liabilities

$340M

Stockholders' Equity

-$120M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$605,000	$43,000	+1307.0%
Gross Profit	$605,000	-$9M	+106.7%
Operating Income	-$221M	-$67M	-230.1%
Net Income	-$222M	-$66M	-237.2%